HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prematures with and without regressed retinopathy of prematurity: comparison of long-term (6-10 years) ophthalmological morbidity.

Abstract
Forty-two ex-prematures having had regressed forms of retinopathy of prematurity (ROP) during the neonatal period were compared with 42 matched non-ROP ex-premature controls at ages 6 to 10 years. The overall incidence of ophthalmologic problems was 55% in the ROP and 36% in the non-ROP group. Strabismus, amblyopia, and refraction anomalies occurred more frequently in the ROP group. In this group, a significantly greater number of children had decreased vision in one or both eyes compared to the non-ROP group. Although the incidence of ophthalmologic problems in the ROP group was considerably higher, the incidence in the non-ROP group still turned out unexpectedly high. this implicates that non-ROP very low birth weight neonates should also be considered to be at a greatly increased risk for later visual problems. Regular ocular examinations, mandatory for the ROP group, thus should be included in follow-up programs of non-ROP very low birthweight neonates as well.
AuthorsB P Cats, K E Tan
JournalJournal of pediatric ophthalmology and strabismus (J Pediatr Ophthalmol Strabismus) Vol. 26 Issue 6 Pg. 271-5 ( 1989) ISSN: 0191-3913 [Print] United States
PMID2621545 (Publication Type: Comparative Study, Journal Article)
Topics
  • Amblyopia (epidemiology, etiology)
  • Child
  • Eye Diseases (epidemiology, etiology)
  • Female
  • Humans
  • Incidence
  • Infant, Newborn
  • Infant, Premature
  • Longitudinal Studies
  • Male
  • Morbidity
  • Netherlands (epidemiology)
  • Refractive Errors (epidemiology, etiology)
  • Retinopathy of Prematurity (complications)
  • Strabismus (epidemiology, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: